

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



東北虎藥業股份有限公司
NORTHEAST TIGER PHARMACEUTICAL CO., LTD.*

(A joint stock limited company established in the People's Republic of China)

(Stock Code: 8197)

**VOLUNTARY ANNOUNCEMENT
ISSUANCE OF NEW DOMESTIC SHARES
UNDER GENERAL MANDATE**

Reference is made to the announcement of the Company dated 13 July 2016 (the “**Announcement**”) regarding, *inter alia*, the issuance of new Domestic Shares under the General Mandate. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

The Company wishes to supplement the Subscription information of the three Subscribers as follows:

- (1) Pursuant to the first subscription agreement dated 13 July 2016 and entered into between Beijing Zhong Jia Hui Tong Investment Management Company Limited* (北京中嘉慧通投資管理有限公司) (“**Subscriber I**”) and the Company, the Company has conditionally agreed to allot and issue 31,500,000 Subscription Shares to Subscriber I at a price of RMB0.89 (equivalent to approximately HK\$1.03^(Note)) per Subscription Share.

Subscriber I is a limited company incorporated in the PRC whose principal business is investment holding.

- (2) Pursuant to the second subscription agreement dated 13 July 2016 and entered into between Beijing Yue Sheng Investment Management Company Limited* (北京悅升投資管理有限責任公司) (“**Subscriber II**”) and the Company, the Company has conditionally agreed to allot and issue 31,500,000 Subscription Shares to Subscriber II at a price of RMB0.89 (equivalent to approximately HK\$1.03^(Note)) per Subscription Share.

Subscriber II is a limited company incorporated in the PRC whose principal business is investment holding.

- (3) Pursuant to the third subscription agreement dated 13 July 2016 and entered into between Mr. Wang Chenqing (王成慶先生) (“**Subscriber III**”) and the Company, the Company has conditionally agreed to allot and issue 7,000,000 Subscription Shares to Subscriber III at a price of RMB0.89 (equivalent to approximately HK\$1.03^(Note)) per Subscription Share.

Effects on shareholding structure

The following supplementary table sets out the shareholding structure of the Company as at the date of the Announcement and immediately after completion of the Subscription (assuming that all of the 70,000,000 new Subscription Shares are subscribed or purchased in full, and the shareholding of H-Shares remains unchanged) as follows:

	As at the date of the Announcement		Upon completion of the Subscription	
	<i>Number of Shares</i>	<i>Approximate % of issued Shares</i>	<i>Number of Shares</i>	<i>Approximate % of issued Shares</i>
Domestic Shares				
Beijing Bao Ying Chuang Fu Investment Management Centre*	398,534,660	53.38	398,534,660	48.80
Guo Feng	137,611,830	18.43	137,611,830	16.85
Zhang Ya Bin	1,618,960	0.22	1,618,960	0.20
Subscriber I	0	0	31,500,000	3.86
Subscriber II	0	0	31,500,000	3.86
Subscriber III	0	0	7,000,000	0.85
Other Shareholders	1,888,790	0.25	1,888,790	0.23
H-Shares				
Public Shareholders	207,000,000	27.72	207,000,000	25.35
Total	746,654,240	100.00	816,654,240	100.00

Further, save as disclosed in this announcement, the remaining contents of the Announcement remains unchanged.

Note: The figures are calculated based on the middle exchange rate of RMB0.8622 to HK\$1 as quoted by The People's Bank of China as at 13 July 2016, being the date of this announcement.

By Order of the Board
東北虎藥業股份有限公司
Northeast Tiger Pharmaceutical Co., Ltd.*
Chairman
Wang Shaoyan

Beijing, the PRC, 14 July 2016

As at the date of this announcement, the Company's executive directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the Company's non-executive directors are Guo Aiqun and Cao Yang and the Company's independent non-executive directors are Zhao Zhen Xing, Chen Youfang and Hui Lai Yam.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

**for identification purposes only*